Epanova® for Lowering Very High Triglycerides

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 399 participants.

Also called NCT01242527

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 399 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01242527
Other papers using this trial's data
  • Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial Journal of clinical lipidology, 2014 DOI, PubMed 24528690

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Denmark, Hungary, India, Netherlands, Russia, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01242527. Randomized; quadruple masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2012-03 (actual). Results posted on 2013-09-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Epanova® for Lowering Very High Triglycerides
Acronym
EVOLVE
Condition
Severe Hypertriglyceridemia
Intervention (Drug)
placebo
Intervention (Drug)
omefas
Intervention (Drug)
omefas
Intervention (Drug)
omefas
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct01242527
Content hash
62bd41bdc88171e2f31c73131191523f60df03c6b0f77ccda91080ae9cc7c975